Question · asked by 1 review

L‐ornithine L‐aspartate vs placebo or no intervention: Non‐serious adverse events assessed using ICH‐GCP

Population
Not specified
Intervention
L‐ornithine L‐aspartate
Comparison
placebo or no intervention
Outcome
Non‐serious adverse events assessed using ICH‐GCP

It is very uncertain whether L‐ornithine L aspartate changes non‐serious adverse events assessed using ICH‐GCP compared with placebo or no intervention (very low certainty).

What each review found

Current versions only
FindingEffectStudiesGRADE certainty
L‐ornithine L aspartate vs placebo or no intervention
Non‐serious adverse events assessed using ICH‐GCP
It is very uncertain whether L‐ornithine L aspartate changes non‐serious adverse events assessed using ICH‐GCP compared with placebo or no intervention (very low certainty).
L‐ornithine L‐aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis (2018) · Cochrane Headline outcomes only
RR 1.15 [0.75, 1.77]14 studies · 1076 participantsVery low

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
L‐ornithine L‐aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis
2018 · Cochrane Headline outcomes only
Not reportedNot extractedNot assessed

The same intervention and outcome, asked in another population or against another comparator.

How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.